Quick answer
GLP-1 receptor research has moved through three stages: characterizing the native incretin hormones GLP-1 and GIP, engineering degradation-resistant and albumin-binding analogues such as semaglutide, and designing unimolecular multi-agonists such as the GIP/GLP-1 agonist tirzepatide and the GIP/GLP-1/glucagon agonist LY3437943. Amylin analogues such as cagrilintide add a parallel receptor family. For a laboratory the useful map is by receptor, signaling bias and assay, not by brand name, and the evidence base mixes in vitro, animal and clinical-stage studies that must be read separately. For laboratory research use only; not for human consumption.
Search interest in GLP-1 peptides is high, and most of what ranks is about products and outcomes in people. This article takes a different approach for research readers: a map of how the receptor field is organized, what primary papers established at each stage, and how to read the evidence without mixing different kinds of study. It sets out vocabulary, a timeline, a receptor-by-compound table and a list of open questions. It does not describe use in people, and the materials discussed are laboratory reagents. The related V8 research materials are listed in the catalog, with receptor background in incretin receptors explained and GLP-1 receptor agonists in research.
Stage 1: native incretin biology
GLP-1 and GIP are the two principal incretin hormones, released from the gut after nutrients arrive and acting on islet beta cells through structurally distinct but related receptors. Baggio and Drucker's review describes both peptides as sharing actions on beta cells, including glucose-dependent insulin secretion, proliferation and resistance to apoptosis, while differing elsewhere: GIP acts on adipose tissue and bone, and GLP-1 slows gastric emptying, inhibits glucagon secretion and promotes satiety (Baggio and Drucker, 2007). Campbell and Drucker's later review contrasts the pharmacology and physiology of the two hormones and discusses non-glycemic actions in multiple tissues, with explicit attention to controversies that preclinical work had not resolved (Campbell and Drucker, 2013). Drucker's 2018 review adds the circuits engaged by endogenous versus pharmacological GLP-1 action and the key GLP-1R-positive cell types (Drucker, 2018).
For laboratory purposes, this stage defines the biology that assays try to reproduce: cAMP generation, insulin secretion from islets or cell lines, receptor internalization and, in vivo, glucose handling and food intake in animals. The native peptides are rapidly inactivated by dipeptidyl peptidase-4, which is the reason all later stages focus on stability.
Stage 2: engineered GLP-1 analogues
The second stage solved the stability problem chemically. Knudsen and Lau's historical review charts the move from short- to long-acting analogues, in which reversible albumin binding through a fatty acid and linker was optimized to extend exposure while keeping receptor potency (Knudsen and Lau, 2019). The primary paper on semaglutide describes a molecule with two amino acid substitutions relative to human GLP-1 (Aib8, Arg34), derivatized at lysine 26, with a GLP-1R affinity of 0.38 nM, three-fold lower than liraglutide but with higher albumin affinity and a 46.1 hour plasma half-life in mini-pigs after intravenous administration (Lau and colleagues, 2015). In receptor biology terms, semaglutide is a mono-agonist at GLP-1R with a long-acting design, which is why it is often the reference compound in assays. A deeper coverage is in the semaglutide research overview and the product listing for semaglutide.
Stage 3: unimolecular multi-agonists
The third stage designs single peptides that engage more than one receptor. Willard and colleagues characterized tirzepatide (LY3298176) as an imbalanced and biased dual agonist: receptor occupancy calculations indicated greater engagement of the GIP receptor than the GLP-1 receptor, tirzepatide mimicked native GIP at the GIP receptor, and at the GLP-1 receptor it favored cAMP generation over β-arrestin recruitment with weaker internalization than native GLP-1; in primary islets, β-arrestin1 limited the insulin response to GLP-1 but not to GIP or tirzepatide (Willard and colleagues, 2020). Coskun and colleagues described LY3437943 as a triple agonist at the glucagon, GIP and GLP-1 receptors with balanced glucagon-receptor and GLP-1R activity and more GIPR activity in vitro, and in obese mice reported lower body weight and improved glycemic control, with glucagon-receptor-mediated energy expenditure adding to the effects attributed to GIPR and GLP-1R (Coskun and colleagues, 2022). Receptor-level detail is in the tirzepatide research overview and the retatrutide research overview, with the compounds listed as tirzepatide and retatrutide.
The parallel amylin axis
Amylin analogues act on a different receptor family. Cagrilintide is described in the primary literature as a long-acting amylin analogue (Kruse and colleagues, 2021). Its relevance to this landscape is as a combination partner in research designs that pair amylin and incretin receptor engagement; the site covers that in the cagrilintide-semaglutide combination article and in cagrilintide vs tirzepatide.
Receptor map by compound
| Compound (research name) | Receptors engaged | Defining feature in the primary literature | Typical research use |
|---|---|---|---|
| Native GLP-1 | GLP-1R | Rapidly degraded by dipeptidyl peptidase-4 | Reference agonist; signaling and internalization controls |
| Semaglutide | GLP-1R | Two substitutions, lysine-26 acylation, albumin binding; 46.1 h half-life in mini-pigs (Lau and colleagues, 2015) | GLP-1R assay reference; long-exposure designs |
| Tirzepatide (LY3298176) | GIPR and GLP-1R | Imbalanced toward GIPR; biased toward cAMP at GLP-1R (Willard and colleagues, 2020) | Dual-receptor and bias studies |
| Retatrutide (LY3437943) | GCGR, GIPR and GLP-1R | Triple agonist with balanced GCGR and GLP-1R activity and more GIPR activity in vitro (Coskun and colleagues, 2022) | Three-receptor signaling studies |
| Cagrilintide | Amylin receptors | Long-acting amylin analogue (Kruse and colleagues, 2021) | Amylin-axis and combination designs |
Brand names are a poor guide to the science, because the same peptide can appear under several names while different peptides can share a category label. The table's purpose is to anchor each compound to its receptors and its primary paper, so a reader can ask of any claim which row it belongs to and which assay would test it.
Brand names are a poor guide to the science. Chemistry-oriented summaries of how branded products relate to the research peptides are in semaglutide brand chemistry and tirzepatide brand chemistry.
Timeline of the field
| Period | Development | Source type |
|---|---|---|
| Early incretin work | GLP-1 and GIP identified as nutrient-released hormones acting on beta cells | Reviews (Baggio and Drucker, 2007) |
| 2000s–2010s | Degradation-resistant and albumin-binding GLP-1 analogues | Knudsen and Lau, 2019; Lau and colleagues, 2015 |
| 2010s | Pharmacology and physiology of incretin action refined; non-glycemic tissue actions explored | Campbell and Drucker, 2013; Drucker, 2018 |
| 2020 | Biased signaling at GLP-1R characterized for a dual agonist | Willard and colleagues, 2020 |
| 2021 | Long-acting amylin analogue described | Kruse and colleagues, 2021 |
| 2022 | Triple GCGR/GIPR/GLP-1R agonist described in vitro and in mice | Coskun and colleagues, 2022 |
The timeline is selective and reflects the primary papers cited here, not a complete history.
How to read evidence in this field
The field mixes evidence types that carry different weight for different questions. A careful reader sorts each cited claim into one of four categories before using it.
- Receptor pharmacology in vitro. Binding, cAMP, β-arrestin recruitment, internalization. Directly relevant to assay design; says nothing about whole-animal outcomes.
- Isolated tissue and primary cells. For example, islets in the Willard study. Closer to physiology, but still a defined preparation.
- Animal models. Obese mice, mini-pigs and others. Useful for mechanism; species differences apply.
- Clinical-stage reports. Several papers cited here also include early-phase human data. Those results describe specific investigational agents in specific studies and are outside the scope of laboratory reagent research, so this article does not draw on them.
A short example shows why. A cAMP potency figure in a cell line, a body-weight change in obese mice and a result in an early-phase study answer three different questions, and a claim that connects them should cite all three, not one. Mixing categories is the most common error in secondary summaries: an in vitro potency figure is quoted beside a clinical outcome as if one explained the other. Keeping them apart also clarifies what a laboratory can actually test with a research reagent: receptor signaling, assay behavior and, in properly approved animal work, mechanism.
Open research questions
- Signaling bias. The tirzepatide study suggests that favoring cAMP over β-arrestin recruitment at GLP-1R may matter for islet insulin responses; how general this is across agonists and cell types is open (Willard and colleagues, 2020).
- Receptor balance. The in vitro balance between GCGR, GIPR and GLP-1R activity of a multi-agonist may not predict its balance in tissues with different receptor expression.
- Mechanism of non-glycemic effects. Reviews flag controversies and uncertainties in incretin biology that need resolution, including the translational relevance of preclinical mechanisms (Campbell and Drucker, 2013).
- Cell-type attribution. Which GLP-1R-positive cells and circuits account for each effect remains an active area (Drucker, 2018).
- Reagent quality. For long, modified peptides, purity, identity and handling matter as much as for any other research peptide; see semaglutide purity testing and tirzepatide purity testing.
A last practical point concerns preparation. Peptides can adsorb to plastic and glass, which lowers delivered concentration in dilute solutions (Goebel-Stengel and colleagues, 2011), so concentration planning and storage follow the same principles as any lyophilized peptide: formula-based arithmetic from the reconstitution calculator, the storage line stated on each product page, and a record of each lot. The comparison across the main compounds is in the 2026 four-compound comparison.
Related reading
- GLP-1 receptor agonists in research
- Incretin receptors explained
- Semaglutide research overview
- Tirzepatide research overview
- Retatrutide research overview
- Research peptide catalog
Frequently asked questions
What is the GLP-1 receptor research landscape in 2026?
A progression from native incretin biology to engineered long-acting GLP-1 analogues such as semaglutide, to dual and triple agonists such as tirzepatide and LY3437943, with amylin analogues such as cagrilintide as a parallel axis.
How is tirzepatide different from semaglutide at the receptor level?
Semaglutide is a GLP-1R agonist. Tirzepatide engages both GIPR and GLP-1R, with greater GIPR engagement and a signaling bias at GLP-1R toward cAMP over β-arrestin recruitment, according to the primary paper.
What receptors does the triple agonist LY3437943 act on?
The glucagon, GIP and GLP-1 receptors. In vitro it shows balanced glucagon-receptor and GLP-1R activity with more GIPR activity.
What is signaling bias at the GLP-1 receptor?
Preferential activation of one downstream pathway, such as cAMP generation, over another, such as β-arrestin recruitment. It is studied because it may change receptor internalization and islet responses.
Why do GLP-1 analogues have fatty-acid side chains?
They allow reversible albumin binding, which prolongs exposure and protects against degradation while keeping receptor potency, as described in the semaglutide discovery paper.
How should I read papers that mix preclinical and clinical data?
Separate them. Use in vitro and animal findings for mechanism and assay design, and regard clinical-stage data as outside the scope of reagent research.
Are these materials for use in people?
No. The research peptides listed on the site are supplied for laboratory research use only, and the studies cited here are discussed only for their receptor and mechanism findings.
Related reading: How GLP-1 Receptor Agonists Work: Signaling and Assays.
References
- Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-57. doi:10.1053/j.gastro.2007.03.054
- Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819-837. doi:10.1016/j.cmet.2013.04.008
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756. doi:10.1016/j.cmet.2018.03.001
- Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155. doi:10.3389/fendo.2019.00155
- Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, et al.. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-80. doi:10.1021/acs.jmedchem.5b00726
- Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, et al.. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):. doi:10.1172/jci.insight.140532
- Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, et al.. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013
- Kruse T, Hansen JL, Dahl K, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64(15):11183-11194. doi:10.1021/acs.jmedchem.1c00565
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
